

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 May 2008 (08.05.2008)

PCT

(10) International Publication Number
WO 2008/053221 A2

(51) International Patent Classification:

C07D 209/08 (2006.01) C07D 403/12 (2006.01)
C07D 239/88 (2006.01) C07C 69/732 (2006.01)

(21) International Application Number:

PCT/GB2007/004176

(22) International Filing Date:

1 November 2007 (01.11.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/864,036 2 November 2006 (02.11.2006) US
60/957,401 22 August 2007 (22.08.2007) US

(71) Applicant (for all designated States except ME, MG, US):
ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ARNOTT, Euan, Alexander [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). CROSBY, John [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). EVANS, Matthew, Charles [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). FORD, James, Gair [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10

2NA (GB). JONES, Martin, Francis [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). LESLIE, Kevin, William [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). MCFARLANE, Ian, Michael [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). SEPENDA, George, Joseph [US/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB).

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

(54) Title: CHEMICAL PROCESS

(57) Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline.



WO 2008/053221 A2